SCHEMBL4039336

SCHEMBL4039336

Cc1nc(O)c(C(C)C)c(O)n1

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10815401 0.84
SCHEMBL12495442 0.76 ADORA2A (0.35)
SCHEMBL3946911 0.72 MAPK1 (0.34) POLBHPGD
SCHEMBL10073170 0.71 KDM5B (0.34)
SCHEMBL9124822 0.70 ALDH1A1 (0.32)
SCHEMBL11100217 0.69
SCHEMBL276022 0.69
SCHEMBL8637167 0.69 KDM4E (0.34) HPGD
SCHEMBL3969708 0.69
SCHEMBL24070513 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332462-B2 Heteroaryl compounds and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2022-05-17 US disclosed
US-20200277286-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2020-09-03 US disclosed
US-10189825-B2 Heteroaryl compounds and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2019-01-29 US disclosed
US-20180118727-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2018-05-03 US disclosed
US-20180002315-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels ACQUIST LLC 2018-01-04 US disclosed
US-20170267681-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES MIDCAP FINANCIAL TRUST, AS AGENT 2017-09-21 US disclosed
US-20150291596-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES BIOCRYST PHARMACEUTICALS, INC. 2015-10-15 US disclosed
US-20150031709-A1 Heteroaryl Compounds and Methods of Use Thereof SUNOVION PHARMACEUTICALS, INC. (US) 2015-01-29 US disclosed
US-20150031709-A1 Heteroaryl Compounds and Methods of Use Thereof SUNOVION PHARMACEUTICALS, INC. (US) 2015-01-29 US disclosed
WO-2013119895-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2013-08-15 WO disclosed
WO-2009019099-A1 TETRASUBSTITUTED PYRIMIDINE DERIVATIVES FOR CONTROLLING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002315-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels XDH, ATIC, DUOX2 POLB 1609/4885HPGD 520/4885
US-20150031709-A1 Heteroaryl Compounds and Methods of Use Thereof COMT, GRIN2C, TPMT POLB 2855/4885HPGD 1450/4885
US-20200277286-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GRIN2C, TPMT POLB 2855/4885HPGD 1450/4885
US-20150291596-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES RNGTT, DUT, RNMT POLB 18/4885HPGD 1535/4885
US-20180118727-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GRIN2C, TPMT POLB 2855/4885HPGD 1450/4885
US-11332462-B2 Heteroaryl compounds and methods of use thereof COMT, GRIN2C, TPMT POLB 2855/4885HPGD 1450/4885
US-10189825-B2 Heteroaryl compounds and methods of use thereof COMT, GRIN2C, TPMT POLB 2855/4885HPGD 1450/4885
US-20170267681-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES RNGTT, DUT, RNMT POLB 18/4885HPGD 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.